DK4172199T3 - Alfa-synuklein-protofibril-bindende antistoffer - Google Patents

Alfa-synuklein-protofibril-bindende antistoffer

Info

Publication number
DK4172199T3
DK4172199T3 DK21765693.3T DK21765693T DK4172199T3 DK 4172199 T3 DK4172199 T3 DK 4172199T3 DK 21765693 T DK21765693 T DK 21765693T DK 4172199 T3 DK4172199 T3 DK 4172199T3
Authority
DK
Denmark
Prior art keywords
protofibril
synuclein
alpha
binding antibodies
antibodies
Prior art date
Application number
DK21765693.3T
Other languages
English (en)
Inventor
Eva Nordström
Jessica Sigvardson
Patrik Nygren
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Application granted granted Critical
Publication of DK4172199T3 publication Critical patent/DK4172199T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK21765693.3T 2020-06-26 2021-06-25 Alfa-synuklein-protofibril-bindende antistoffer DK4172199T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27
PCT/IB2021/000440 WO2021260434A1 (en) 2020-06-26 2021-06-25 α-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES

Publications (1)

Publication Number Publication Date
DK4172199T3 true DK4172199T3 (da) 2025-08-18

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21765693.3T DK4172199T3 (da) 2020-06-26 2021-06-25 Alfa-synuklein-protofibril-bindende antistoffer

Country Status (27)

Country Link
US (2) US11339212B2 (da)
EP (2) EP4570315A3 (da)
JP (2) JP7337959B2 (da)
KR (1) KR20230027095A (da)
CN (1) CN115803341A (da)
AU (1) AU2021298222A1 (da)
CA (1) CA3181207A1 (da)
DK (1) DK4172199T3 (da)
ES (1) ES3037420T3 (da)
FI (1) FI4172199T3 (da)
HR (1) HRP20250812T1 (da)
HU (1) HUE072262T2 (da)
IL (1) IL298584B2 (da)
LT (1) LT4172199T (da)
MA (1) MA60122B1 (da)
MD (1) MD4172199T2 (da)
MX (1) MX2022016005A (da)
PH (1) PH12022552829A1 (da)
PL (1) PL4172199T3 (da)
PT (1) PT4172199T (da)
RS (1) RS66984B1 (da)
SI (1) SI4172199T1 (da)
SM (1) SMT202500274T1 (da)
TW (1) TWI879983B (da)
UY (1) UY39295A (da)
WO (1) WO2021260434A1 (da)
ZA (1) ZA202211843B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE072262T2 (hu) 2020-06-26 2025-11-28 Bioarctic Ab Alfa-szinuklein protofibrillum-kötõ antitestek
WO2026068513A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Bispecific binding molecule

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
WO1995007301A1 (en) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
ATE312349T1 (de) 1998-07-03 2005-12-15 Innogenetics Nv Differentielle diagnose von neurodegeneration
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2009525046A (ja) 2006-01-31 2009-07-09 エラン ファーマシューティカルズ，インコーポレイテッド アルファ−シヌクレインキナーゼ
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
DK2282758T3 (da) 2008-04-29 2019-02-25 Bioarctic Ab Antistoffer og vacciner til anvendelse i terapeutiske og diagnostiske fremgangsmåder for alpha-synuclein-relaterede lidelser
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20120100129A1 (en) 2009-06-29 2012-04-26 Gellerfors Paer N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
UY33578A (es) * 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CN103796679B (zh) * 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP4043493A1 (en) * 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EP3359569A2 (en) * 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
HUE072262T2 (hu) 2020-06-26 2025-11-28 Bioarctic Ab Alfa-szinuklein protofibrillum-kötõ antitestek

Also Published As

Publication number Publication date
EP4570315A2 (en) 2025-06-18
WO2021260434A1 (en) 2021-12-30
HRP20250812T1 (hr) 2025-09-12
JP2023159299A (ja) 2023-10-31
SMT202500274T1 (it) 2025-09-12
SI4172199T1 (sl) 2025-08-29
CA3181207A1 (en) 2021-12-30
TWI879983B (zh) 2025-04-11
PT4172199T (pt) 2025-08-11
HUE072262T2 (hu) 2025-11-28
JP2023525174A (ja) 2023-06-15
IL298584A (en) 2023-01-01
IL298584B1 (en) 2024-06-01
PH12022552829A1 (en) 2023-06-14
US20210403542A1 (en) 2021-12-30
ZA202211843B (en) 2024-02-28
TW202212357A (zh) 2022-04-01
US11339212B2 (en) 2022-05-24
CN115803341A (zh) 2023-03-14
EP4570315A3 (en) 2025-09-17
US20230080536A1 (en) 2023-03-16
UY39295A (es) 2022-01-31
MA60122B1 (fr) 2025-07-31
EP4172199B1 (en) 2025-05-14
ES3037420T3 (en) 2025-10-01
MX2022016005A (es) 2023-02-02
IL298584B2 (en) 2024-10-01
JP7337959B2 (ja) 2023-09-04
MD4172199T2 (ro) 2025-09-30
RS66984B1 (sr) 2025-07-31
FI4172199T3 (fi) 2025-08-12
PL4172199T3 (pl) 2025-09-22
AU2021298222A1 (en) 2022-12-15
EP4172199A1 (en) 2023-05-03
KR20230027095A (ko) 2023-02-27
LT4172199T (lt) 2025-07-10

Similar Documents

Publication Publication Date Title
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
KR102763158B9 (ko) 최적화된 항tl1a 항체
EP3822289A4 (en) ANTI-SIRP-ALPHA ANTIBODIES
EP3950061A4 (en) ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
IL311039A (en) Anti-cd3 antibodies
DK4214240T3 (da) Anti-ccr8-antistoffer
EP3797122A4 (en) Anti-ror antibody constructs
EP3941944A4 (en) Claudin-6 bispecific antibodies
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP4243860A4 (en) ANTI-CD25 ANTIBODIES
IL311043A (en) Anti-il-11rα antibodies
IL310245A (en) Anti-hla-g antibodies
EP4463485A4 (en) Tetrahedral antibodies
EP4081539A4 (en) Novel anti-fgfr2b antibodies
EP3995582A4 (en) ANTI-EPHA4 ANTIBODIES
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
IL289252A (en) Ep2 antagonist
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
IL281594A (en) Anti-klrg1 antibodies
EP4185612A4 (en) Anti-abeta antibodies
DK4157876T3 (da) Anti-pd-1-antistoffer
IL292799A (en) Anti-siglec-9 antibody molecules
EP4163301C0 (en) Humanized Anti-GPC-1 Antibody
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies